日韩中文字幕在线一区二区三区,亚洲热视频在线观看,久久精品午夜一区二区福利,精品一区二区三区在线观看l,麻花传媒剧电影,亚洲香蕉伊综合在人在线,免费av一区二区三区在线,亚洲成在线人视频观看
          首頁(yè) 500強(qiáng) 活動(dòng) 榜單 商業(yè) 科技 商潮 專(zhuān)題 品牌中心
          雜志訂閱

          全球新冠疫苗接種數(shù)超過(guò)10億劑,這個(gè)小國(guó)接種率第一

          Sy Mukherjee
          2021-04-28

          能夠在如此短的時(shí)間內(nèi)讓世界上近13%的人口進(jìn)行疫苗接種,令人驚嘆。

          文本設(shè)置
          小號(hào)
          默認(rèn)
          大號(hào)
          Plus(0條)

          4月25日凌晨,全球新冠疫苗的接種數(shù)量突破了10億劑大關(guān)。在新冠疫情爆發(fā)僅短短一年多的時(shí)間里,即完成如此大規(guī)模的疫苗接種,是史無(wú)前例的。疫苗研發(fā)的速度如此之快本身就是一項(xiàng)驚人的壯舉,而能夠克服現(xiàn)實(shí)困難,在如此短的時(shí)間內(nèi)讓世界上近13%的人口進(jìn)行疫苗接種,則更加令人驚嘆。

          在此需要說(shuō)明的是,這并不是說(shuō),目前已經(jīng)有大約八分之一的世界人口完成了疫苗接種。因?yàn)檫@10億劑已經(jīng)使用的疫苗中,不僅有單針接種式疫苗,還含有雙針接種式疫苗類(lèi)型。

          然而,疫苗分配呈現(xiàn)出了區(qū)域分布不均、極度失衡的局面,接種進(jìn)度因國(guó)而異。在美國(guó),可能有50%以上的成年人至少接受過(guò)一次疫苗接種,而亞非國(guó)家的速度則明顯較慢。僅占全球總?cè)丝?6%的高收入國(guó)家,接種疫苗數(shù)占了總體的47%。

          世界各地,尤其是發(fā)展中國(guó)家,一直在通過(guò)“新冠肺炎疫苗實(shí)施計(jì)劃”(COVAX)來(lái)獲取疫苗,這是由世界衛(wèi)生組織(WHO)、全球疫苗免疫聯(lián)盟(Gavi)等全球衛(wèi)生治理的重要參與者共同提出并牽頭進(jìn)行的項(xiàng)目。

          下面將詳細(xì)介紹這10億多劑疫苗的相關(guān)細(xì)節(jié),比如各國(guó)的疫苗接種情況,以及不同疫苗在各個(gè)國(guó)家和地區(qū)的應(yīng)用情況。

          哪些國(guó)家在疫苗接種方面做得最好?

          迄今為止,發(fā)達(dá)國(guó)家的疫苗接種進(jìn)度更快。這一結(jié)果符合常理,因?yàn)榘l(fā)達(dá)國(guó)家擁有健全的醫(yī)療體系,而許多發(fā)展中國(guó)家至今還缺乏一些相關(guān)醫(yī)療基礎(chǔ)設(shè)施。

          目前,全球的接種速度達(dá)每天約1600萬(wàn)劑次。但重要的是,我們要搞清楚接種劑量數(shù)和接種人口比例的區(qū)別。

          在完成疫苗接種(即已經(jīng)打過(guò)兩針雙針接種式疫苗,例如輝瑞疫苗;或打過(guò)一針單針接種式疫苗,比如強(qiáng)生疫苗)的人口比例方面,以色列處于領(lǐng)先地位。據(jù)《紐約時(shí)報(bào)》(New York Times)報(bào)道,該國(guó)已經(jīng)有56%的人口完成了疫苗接種,61%的人口接種了至少一劑新冠疫苗。上周末,以色列已經(jīng)連續(xù)兩天新冠死亡病例零新增。

          但是以色列的國(guó)土面積很小,僅有900萬(wàn)左右人口,而且該國(guó)的疫苗初期推廣措施也很完善。美國(guó)疾病控制和預(yù)防中心(CDC)的數(shù)據(jù)顯示,在世界人口較多的國(guó)家中,美國(guó)的疫苗推廣速度驚人,迄今為止已經(jīng)接種了近2.29億劑疫苗,有近9500萬(wàn)人完成了疫苗接種。

          哪些國(guó)家在疫苗接種方面表現(xiàn)不佳?

          也有一些國(guó)家的疫苗接種進(jìn)度緩慢。據(jù)統(tǒng)計(jì),許多國(guó)家的居民接種疫苗率為零。

          在疫苗接種進(jìn)度方面落后的國(guó)家主要分布在非洲、中東和亞洲,包括巴林、菲律賓、越南、巴基斯坦、尼日利亞、贊比亞、伊朗和伊拉克。

          澳大利亞在暫停向50歲以下人群接種(其主要使用并且可以在當(dāng)?shù)厣a(chǎn)的)阿斯利康疫苗后,該國(guó)的疫苗接種速度正在明顯變緩。而盡管印度在疫苗研發(fā)方面做得相對(duì)較好,但其面臨的疫苗接種難題,讓該國(guó)的疫苗接種人口比例一直難以提高。這個(gè)人口稠密的國(guó)家目前正在面臨著一場(chǎng)大規(guī)模的新冠疫情危機(jī),僅4月23日當(dāng)天即新增新冠肺炎確診病例33萬(wàn)例。

          全球使用量最大的新冠疫苗

          根據(jù)新冠疫苗追蹤系統(tǒng)的數(shù)據(jù),美國(guó)食品與藥品監(jiān)督管理局(FDA)在美國(guó)本土僅批準(zhǔn)了三款新冠疫苗的緊急使用,分別為輝瑞(Pfizer)/BioNTech、Moderna和強(qiáng)生(Johnson & Johnson)的疫苗。而總計(jì)110種正在研發(fā)的新冠疫苗中,全球已經(jīng)上市或緊急批準(zhǔn)了其中14款。

          目前,歐洲及澳大利亞的疫苗接種速度緩慢且混亂,這啟示我們,一個(gè)地區(qū)所依賴(lài)的疫苗品牌,能夠?qū)σ呙缃臃N進(jìn)度產(chǎn)生決定性作用。

          由于潛在的凝血問(wèn)題,世界衛(wèi)生組織正在審查牛津大學(xué)(University of Oxford)和阿斯利康(AstraZeneca)合作研發(fā)的新冠疫苗的現(xiàn)有數(shù)據(jù)。該款新冠疫苗是應(yīng)用范圍最廣的一款疫苗,目前有135個(gè)國(guó)家批準(zhǔn)了它的使用。隨后是輝瑞/BioNTech和Moderna的雙針接種式mRNA疫苗,接著是中國(guó)國(guó)藥集團(tuán)的新冠滅活疫苗。

          上圖清晰顯示出了疫苗使用的地區(qū)性差異。正如所預(yù)料,高收入國(guó)家,尤其是美國(guó),主要依賴(lài)的是獲得了緊急使用授權(quán),并且可以在當(dāng)?shù)厣a(chǎn)的輝瑞和Moderna疫苗。中國(guó)一直在使用本土疫苗。而盡管俄羅斯本國(guó)的疫苗接種比例并不特別高,其正在積極向其它國(guó)家推廣“衛(wèi)星-V”疫苗。

          其余國(guó)家主要使用的疫苗,美國(guó)人則可能甚至都沒(méi)有聽(tīng)說(shuō)過(guò)。之后我們所要面臨的問(wèn)題是,這些疫苗是否仍然能夠起到預(yù)防新冠病毒的作用。(財(cái)富中文網(wǎng))

          譯者:Claire

          4月25日凌晨,全球新冠疫苗的接種數(shù)量突破了10億劑大關(guān)。在新冠疫情爆發(fā)僅短短一年多的時(shí)間里,即完成如此大規(guī)模的疫苗接種,是史無(wú)前例的。疫苗研發(fā)的速度如此之快本身就是一項(xiàng)驚人的壯舉,而能夠克服現(xiàn)實(shí)困難,在如此短的時(shí)間內(nèi)讓世界上近13%的人口進(jìn)行疫苗接種,則更加令人驚嘆。

          在此需要說(shuō)明的是,這并不是說(shuō),目前已經(jīng)有大約八分之一的世界人口完成了疫苗接種。因?yàn)檫@10億劑已經(jīng)使用的疫苗中,不僅有單針接種式疫苗,還含有雙針接種式疫苗類(lèi)型。

          然而,疫苗分配呈現(xiàn)出了區(qū)域分布不均、極度失衡的局面,接種進(jìn)度因國(guó)而異。在美國(guó),可能有50%以上的成年人至少接受過(guò)一次疫苗接種,而亞非國(guó)家的速度則明顯較慢。僅占全球總?cè)丝?6%的高收入國(guó)家,接種疫苗數(shù)占了總體的47%。

          世界各地,尤其是發(fā)展中國(guó)家,一直在通過(guò)“新冠肺炎疫苗實(shí)施計(jì)劃”(COVAX)來(lái)獲取疫苗,這是由世界衛(wèi)生組織(WHO)、全球疫苗免疫聯(lián)盟(Gavi)等全球衛(wèi)生治理的重要參與者共同提出并牽頭進(jìn)行的項(xiàng)目。

          下面將詳細(xì)介紹這10億多劑疫苗的相關(guān)細(xì)節(jié),比如各國(guó)的疫苗接種情況,以及不同疫苗在各個(gè)國(guó)家和地區(qū)的應(yīng)用情況。

          哪些國(guó)家在疫苗接種方面做得最好?

          迄今為止,發(fā)達(dá)國(guó)家的疫苗接種進(jìn)度更快。這一結(jié)果符合常理,因?yàn)榘l(fā)達(dá)國(guó)家擁有健全的醫(yī)療體系,而許多發(fā)展中國(guó)家至今還缺乏一些相關(guān)醫(yī)療基礎(chǔ)設(shè)施。

          目前,全球的接種速度達(dá)每天約1600萬(wàn)劑次。但重要的是,我們要搞清楚接種劑量數(shù)和接種人口比例的區(qū)別。

          在完成疫苗接種(即已經(jīng)打過(guò)兩針雙針接種式疫苗,例如輝瑞疫苗;或打過(guò)一針單針接種式疫苗,比如強(qiáng)生疫苗)的人口比例方面,以色列處于領(lǐng)先地位。據(jù)《紐約時(shí)報(bào)》(New York Times)報(bào)道,該國(guó)已經(jīng)有56%的人口完成了疫苗接種,61%的人口接種了至少一劑新冠疫苗。上周末,以色列已經(jīng)連續(xù)兩天新冠死亡病例零新增。

          但是以色列的國(guó)土面積很小,僅有900萬(wàn)左右人口,而且該國(guó)的疫苗初期推廣措施也很完善。美國(guó)疾病控制和預(yù)防中心(CDC)的數(shù)據(jù)顯示,在世界人口較多的國(guó)家中,美國(guó)的疫苗推廣速度驚人,迄今為止已經(jīng)接種了近2.29億劑疫苗,有近9500萬(wàn)人完成了疫苗接種。

          哪些國(guó)家在疫苗接種方面表現(xiàn)不佳?

          也有一些國(guó)家的疫苗接種進(jìn)度緩慢。據(jù)統(tǒng)計(jì),許多國(guó)家的居民接種疫苗率為零。

          在疫苗接種進(jìn)度方面落后的國(guó)家主要分布在非洲、中東和亞洲,包括巴林、菲律賓、越南、巴基斯坦、尼日利亞、贊比亞、伊朗和伊拉克。

          澳大利亞在暫停向50歲以下人群接種(其主要使用并且可以在當(dāng)?shù)厣a(chǎn)的)阿斯利康疫苗后,該國(guó)的疫苗接種速度正在明顯變緩。而盡管印度在疫苗研發(fā)方面做得相對(duì)較好,但其面臨的疫苗接種難題,讓該國(guó)的疫苗接種人口比例一直難以提高。這個(gè)人口稠密的國(guó)家目前正在面臨著一場(chǎng)大規(guī)模的新冠疫情危機(jī),僅4月23日當(dāng)天即新增新冠肺炎確診病例33萬(wàn)例。

          全球使用量最大的新冠疫苗

          根據(jù)新冠疫苗追蹤系統(tǒng)的數(shù)據(jù),美國(guó)食品與藥品監(jiān)督管理局(FDA)在美國(guó)本土僅批準(zhǔn)了三款新冠疫苗的緊急使用,分別為輝瑞(Pfizer)/BioNTech、Moderna和強(qiáng)生(Johnson & Johnson)的疫苗。而總計(jì)110種正在研發(fā)的新冠疫苗中,全球已經(jīng)上市或緊急批準(zhǔn)了其中14款。

          目前,歐洲及澳大利亞的疫苗接種速度緩慢且混亂,這啟示我們,一個(gè)地區(qū)所依賴(lài)的疫苗品牌,能夠?qū)σ呙缃臃N進(jìn)度產(chǎn)生決定性作用。

          由于潛在的凝血問(wèn)題,世界衛(wèi)生組織正在審查牛津大學(xué)(University of Oxford)和阿斯利康(AstraZeneca)合作研發(fā)的新冠疫苗的現(xiàn)有數(shù)據(jù)。該款新冠疫苗是應(yīng)用范圍最廣的一款疫苗,目前有135個(gè)國(guó)家批準(zhǔn)了它的使用。隨后是輝瑞/BioNTech和Moderna的雙針接種式mRNA疫苗,接著是中國(guó)國(guó)藥集團(tuán)的新冠滅活疫苗。

          上圖清晰顯示出了疫苗使用的地區(qū)性差異。正如所預(yù)料,高收入國(guó)家,尤其是美國(guó),主要依賴(lài)的是獲得了緊急使用授權(quán),并且可以在當(dāng)?shù)厣a(chǎn)的輝瑞和Moderna疫苗。中國(guó)一直在使用本土疫苗。而盡管俄羅斯本國(guó)的疫苗接種比例并不特別高,其正在積極向其它國(guó)家推廣“衛(wèi)星-V”疫苗。

          其余國(guó)家主要使用的疫苗,美國(guó)人則可能甚至都沒(méi)有聽(tīng)說(shuō)過(guò)。之后我們所要面臨的問(wèn)題是,這些疫苗是否仍然能夠起到預(yù)防新冠病毒的作用。(財(cái)富中文網(wǎng))

          譯者:Claire

          Something extraordinary, and extraordinarily rare, happened in the wee hours of April 25: The world administered its 1-billionth-plus dose of a COVID vaccine. Reaching such a milestone in just more than a year of a global pandemic is unprecedented and the fruits of an immunization campaign the likes of which we've never seen before. Creating vaccines this quickly is an impressive feat in and of itself, but nearly 13% of the world's population actually getting vaccinated is arguably an even more impressive accomplishment given the practical roadblocks.

          To be clear: This doesn't mean about an eighth of the entire world has been fully vaccinated. It just means that many doses have been administered, whether as part of a one-dose or two-dose regimen.

          But stark geographical differences remain, resulting in a lopsided vaccine rollout. Depending on which country you're talking about, more than 50% of the adult population may have received at least one shot (as is the case in the U.S.) while nations in Africa or Asia are moving at a significantly slower pace. While high-income nations make up just 16% of the global population, they have administered 47% of COVID vaccine doses to date。

          The world at large, particularly developing countries, has been relying on a partnership called COVAX, which incorporates global health players running the gamut from the World Health Organization (WHO) to vaccine alliances such as Gavi.

          From how different nations have been coping with their vaccine rollouts to the companies creating jabs that go to different regions, here's where the world stands more than 1 billion doses in.

          Which countries have done the best on vaccination?

          To date, nations with more advanced economies have made more progress in vaccinating their populations. That's not exactly shocking, given the lack of health care infrastructure in many developing nations and the fact that other countries, usually wealthy, bought up supplies early on.

          There are, on average, about 16 million doses being administered per day. But it's important to differentiate the total number of shots in arms in a given country versus the per capita total.

          If we focus on fully vaccinated individuals, or those who have received two doses of the vaccines such as Pfizer/BioNTech’s, which require a dual-shot combo, or of a single-dose vaccine such as Johnson & Johnson's, Israel is doing the best with 56% of its population fully vaccinated and 61% at least partially vaccinated, according to the New York Times. Over the weekend, the country achieved the milestone of zero recorded COVID-related deaths two days in a row.

          But Israel has a population of about 9 million people and a significantly smaller land mass, on top of a well-heeled initial vaccine rollout. Among the more populous nations in the world, the United States has been moving at an impressive clip, with nearly 229 million doses administered to date and nearly 95 million people fully vaccinated, according to the CDC.

          Which countries are struggling with COVID vaccinations?

          There are also nations struggling with the vaccine ramp-up. Multiple countries have what results in a statistical zero percent of their residents vaccinated at all.

          The bulk of the nations lagging in the vaccination effort spans Africa, the Middle East, and Asia. That includes Bahrain, the Philippines, Vietnam, Pakistan, Nigeria, Zambia, Iran, and Iraq.

          Australia has been facing a massive slump in its own vaccination campaign as it pauses AstraZeneca's shot, which it primarily relies on and can manufacture locally, for those under the age of 50. And while India has done relatively well in its vaccination campaign, last-mile problems have made it difficult to get the numbers up on a per capita basis. The densely populated nation is now facing a massive COVID crisis, with 330,000 new cases detected on April 23 alone.

          The most-used COVID vaccines around the globe

          Just three COVID vaccines, from Pfizer/BioNTech, Moderna, and Johnson & Johnson, are FDA-authorized in the U.S. But around the globe, there are currently 110 COVID vaccine candidates with 14 approved, according to the COVID-19 Vaccine Tracker.

          As the example of Europe's and Australia's chaotic vaccine rollout has underscored, the kinds of vaccines a region relies on can dictate the course of their immunization campaigns.

          Oxford and AstraZeneca's vaccine, which has faced scrutiny regarding potential blood clotting side effects, is being administered in the most countries by far—135 to be exact. Next comes the Pfizer/BioNTech and Moderna two-dose mRNA vaccines, followed by China-based Sinopharm's jab.

          The trend clearly shows regional preferences. Higher-income nations, and especially the United States, have predictably relied on the first authorized vaccines from Pfizer and Moderna, which are manufactured locally. China has gone with its own local player. And Russia has made aggressive pacts to get its Sputnik COVID shot to other countries even though the country itself doesn't have a particularly high percentage of its population vaccinated.

          Other nations are relying on vaccines that Americans likely haven't even heard of. The question in the coming months is whether this vaccine diaspora can still lead to global protection against the coronavirus.

          財(cái)富中文網(wǎng)所刊載內(nèi)容之知識(shí)產(chǎn)權(quán)為財(cái)富媒體知識(shí)產(chǎn)權(quán)有限公司及/或相關(guān)權(quán)利人專(zhuān)屬所有或持有。未經(jīng)許可,禁止進(jìn)行轉(zhuǎn)載、摘編、復(fù)制及建立鏡像等任何使用。
          0條Plus
          精彩評(píng)論
          評(píng)論

          撰寫(xiě)或查看更多評(píng)論

          請(qǐng)打開(kāi)財(cái)富Plus APP

          前往打開(kāi)